ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for Susan Lucas
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.06 - 9.20
Open     -
Vol / Avg. 0.00/106,317.00
Mkt cap 327.27M
P/E     -
Div/yield     -
EPS -1.10
Shares 43.69M
Beta 0.42
Inst. own 63%
Aug 3, 2015
Q2 2015 ChemoCentryx Inc Earnings Release (Estimated) Add to calendar
May 19, 2015
ChemoCentryx Inc at UBS Global Healthcare Conference
May 6, 2015
Q1 2015 ChemoCentryx Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 ChemoCentryx Inc Earnings Release
Mar 12, 2015
Q4 2014 ChemoCentryx Inc Earnings Call - Webcast
Mar 12, 2015
Q4 2014 ChemoCentryx Inc Earnings Release
Mar 3, 2015
ChemoCentryx Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.94% -34.84%
Return on average equity -46.30% -36.96%
Employees 58 -
CDP Score - -


850 Maude Ave
MOUNTAIN VIEW, CA 94043-4022
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company focuses on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors and chemo-attractant receptors. The Company has five drug candidates in clinical development, which include CCX168, CCX140, CCX872, Traficet-EN and CCX507. CCX168 targets the chemo-attractant C5a receptor, which binds to a fragment of the complement protein known as C5. CCX140 targets the chemokine receptor known as CCR2. CCX872 is the Company’s second generation CCR2 inhibitor for the treatment of metabolic diseases, such as atherosclerosis and cardiovascular disease. Traficet-EN is intended to control the inflammatory response by targeting the chemokine receptor known as CCR9. CCX507 works in the area of CCR9 inhibitors.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 52
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 54
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Age: 65
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 54
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Ira Klein M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 50
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters